Home > Nanotechnology Columns > NanotechnologyKTN > NanoKTN NanoRegen Mission Report
 |
Fiona Brewer NanoKTN |
Abstract:
In September this year, NanoKTN hosted its NanoRegen Mission to Germany and Austria, organised in partnership with the Science and Innovation Network, Berlin and Chemistry Innovation KTN.
December 20th, 2012
NanoKTN NanoRegen Mission Report
These popular international missions raise the profile of UK nanotechnology, providing SMEs with opportunities to drive forward international business development by helping to foster links with overseas suppliers and potential customers, ensuring the future of UK nanotechnology is embedded in the global market.
Following the mission, The NanoKTN is hosting a dissemination event at UCL in conjunction with the LRMN (London Regenerative Medicine Network) with an evening reception sponsored by Miltenyi on the 30th January 2013. More information can be found at the NanoKTN website https://connect.innovateuk.org/web/nanomite/articles/-/blogs/nanoregen-mission-dissemination-event-date-for-your-diary?ns_33_redirect=%2Fweb%2Fnanomite%2Farticles%3Fp_p_id%3D33
Post Report NanoRegen Mission 2012 to Germany & Austria
In September this year, NanoKTN hosted its NanoRegen Mission to Germany and Austria, organised in partnership with the Science and Innovation Network, Berlin and Chemistry Innovation KTN. These popular international missions raise the profile of UK nanotechnology, providing SMEs with opportunities to drive forward international business development by helping to foster links with overseas suppliers and potential customers, ensuring the future of UK nanotechnology is embedded in the global market.
The UK delegation comprised The Electrospinning Company, Giltech Ltd, Neotherix, Orla Protein Technologies Ltd, Pharmidex and University of Oxford, all interested in developing strategic links with Europe in order to build effective working relationships in the area of advanced biomaterials and regenerative medicine. The mission was led by Professor Chris Mason, Head of the Regenerative Medicine Bioprocess Group in the Advanced Centre for Biochemical Engineering at UCL. All the delegates spoke at the workshops arranged at the Fraunhofer IZI, Leipzig, LISAvienna Group and the British Embassy, Berlin and attended the 3rd TERMIS World Congress.
Following the mission, The NanoKTN is hosting a dissemination event at UCL in conjunction with the LRMN (London Regenerative Medicine Network) with an evening reception sponsored by Miltenyi on the 30th January 2013. More information can be found at the NanoKTN website https://connect.innovateuk.org/web/nanomite/articles/-/blogs/nanoregen-mission-dissemination-event-date-for-your-diary?ns_33_redirect=%2Fweb%2Fnanomite%2Farticles%3Fp_p_id%3D33
Dr Felicity Sartain, Theme Manager at the NanoKTN comments on the aims of the mission, "One of the strategic highlights from the UK Strategy for Regenerative Medicine, was engagement with international partners to establish strong networks and relationships, through which new opportunities may arise that can be capitalised upon. By hosting these missions, the NanoKTN aims to deliver on these objectives, helping to raise the profile of UK nanotechnology, providing UK SMEs with opportunities to drive forward international business development and we look forward to seeing how the potentials for collaboration with German and Austrian companies and research institutions develop."
The cell therapy industry is expected to be worth £3.1 billion by 2014 with even greater growth predicted beyond that. Currently the UK is in a strong position to gain a significant share of this new market due to its leading position in regenerative medicine and biomaterials research, as well as the technological developments being exploited primarily in SMEs and some larger industries. It is imperative that with such a strong science base, the UK strives to build appropriate links and collaborations in order to realise the prospective commercial opportunities.
With Germany's strengths in regenerative medicine and notable investments in this field, namely the cell-based therapies initiative (€30 million, 2005-2009) and stem cell initiative (€9 million, 2008-2012) and Austria's recent emergence in red biotechnologies and funding program for nanostructured materials for use in Life Sciences, they respectively provide thriving mature and, comparably, new arenas in which to operate. Furthermore, similar to the UK, they recognise the need for development of innovative biomaterials and their processing, which can make a decisive contribution to the broad clinical application of regenerative medicine, thus were chosen as promising places where new and valuable connections could be initiated.
The UK, Germany, and Austria, have considerable expertise within this multidisciplinary field, and further product developments will continue to require the convergence and co-operation of the life, physical, engineering, nanotechnological and clinical sciences. Companies and academic institutions need to find collaborators in order to be able to resolve complex multidisciplinary challenges, and with whom new concepts can be developed.
Following on from these workshops and meetings it will be important to capture and communicate the information obtained, and build upon individual interactions and momentum that has been generated, so to convert these interactions into helping the establishment of cell therapy as the fourth and final pillar of healthcare.
A full copy of the mission report will be available at the dissemination event on the 30th January 2013 and by emailing
NanoRegen Focus Group
To stay up-to-date with the NanoKTN's work within regenerative medicine, you can join the NanoRegen focus group, for free by visiting www.nanoktn.com. This group was set up to aid the advances in nano-structured materials and biomaterials for use in tissue engineering. NanoRegen brings together researchers, clinicians, industrialists and other experts in this area to enable this community to share ideas and experience, collaborate effectively and to secure the project funding which allows the development and commercialisation of key opportunities.
About NanoKTN
The NanoKTN facilitates the transfer of knowledge and experience between industry and research, offering companies dealing in small-scale technology access to information on new processes, patents and funding as well as keeping up-to-date with industry regulation. The four broad areas that the NanoKTN focuses on are: Promoting and facilitating knowledge exchange, supporting the growth of UK capabilities, raising awareness of Nanotechnology, and providing thought leadership and input to UK policy and strategy.
About the Chemistry Innovation KTN
Chemistry Innovation is the Knowledge Transfer Network (KTN) for the chemistry-using industries. It is industry led and backed by the Technology Strategy Board. Chemistry is a key-enabling science for a major part of the UK economy and it is Chemistry Innovation's mission to support the chemistry-using industries and to drive innovation and value for them. This includes chemical and pharmaceutical sectors such as healthcare, home and personal care, food and drink, polymers, crop protection and lubricants, as well as sections which require substantial chemistry input.
The combined value of the UK chemistry-using industries is a total GVA of over £270 billion. Chemistry innovation works on the community's behalf to deliver: Unique networking opportunities; project identification and collaboration; an influential voice to funders and strategy makers & a coherent strategy and priorities. Linking UK SMEs to collaborative partners in the UK and abroad is a key priority.
Bookmark:
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||